OncoMatch/Clinical Trials/NCT06741982
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Is NCT06741982 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Lysogenic HSV virus. and Tislelizumab for hnscc.
Treatment: Lysogenic HSV virus. · Tislelizumab · Afatinib — Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Allowed: HPV HPV-negative
Non oropharyngeal HNSCC carcinoma and HPV-negative oropharyngeal carcinoma, stages III, IVA and IVB; HPV status of oropharyngeal cancer will be determined by p16 immunohistochemistry.
Allowed: HPV HPV-positive
HPV-positive oropharyngeal cancers, stages II and III; HPV status of oropharyngeal cancer will be determined by p16 immunohistochemistry.
Disease stage
Required: Stage III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
prior use of PD-1 antibody
Cannot have received: anti-PD-L1 therapy
prior use of PD-L1 antibody
Cannot have received: anti-CTLA-4 therapy
prior use of CTLA-4 antibody
Cannot have received: EGFR-targeted therapy
prior use of EGFR antibody, or EGFR-TKI
Cannot have received: anti-tumor vaccine
received an anti-tumor vaccine
Cannot have received: investigational drug
received any investigational drug within 4 weeks prior to the first dose of study drug
Lab requirements
Blood counts
adequate organ and bone marrow function as defined below
Kidney function
adequate organ and bone marrow function as defined below
Liver function
adequate organ and bone marrow function as defined below
Cardiac function
abnormal class II or higher cardiac function (NYHA criteria), ischemic heart disease, clinically significant arrhythmia, ejection fraction <50%, QTc interval >450 msec in men and >470 msec in women
Have adequate organ and bone marrow function as defined below; serious medical conditions such as abnormal class II or higher cardiac function (NYHA criteria), ischemic heart disease (e.g., myocardial infarction or angina pectoris), clinically significant supraventricular or ventricular arrhythmia with echocardiographic ejection fraction <50%; QTc interval, >450 msec in men and >470 msec in women
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify